Krystal Biotech, Inc.

NasdaqGS:KRYS Stock Report

Market Cap: US$4.8b

Krystal Biotech Future Growth

Future criteria checks 5/6

Krystal Biotech is forecast to grow earnings and revenue by 31.9% and 25.8% per annum respectively. EPS is expected to grow by 32.2% per annum. Return on equity is forecast to be 16.3% in 3 years.

Key information

31.9%

Earnings growth rate

32.2%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate25.8%
Future return on equity16.3%
Analyst coverage

Good

Last updated10 Apr 2025

Recent future growth updates

Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 07
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Recent updates

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Feb 21

Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing

Dec 18
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing

Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 07
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Oct 14
author-image

Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge

Aug 29 International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 31

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

May 13
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Feb 28

Krystal Biotech: Ready For Launch

Feb 20

We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Jan 02
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth

Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Sep 06
Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth

Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

Aug 08
Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

May 17
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Jan 30
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Krystal Biotech cleared to file EU marketing application for rare skin disease therapy

Sep 22

We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Aug 30
We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth

Krystal Biotech: Solid Performance, Let's Keep Holding

Aug 18

Krystal Biotech GAAP EPS of -$1.10 misses by $0.07

Aug 08

Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis

Aug 01

Krystal Biotech: High Potential, Buy-At-Dips Stock

May 25

We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Apr 20
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqGS:KRYS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027824445420N/A7
12/31/2026666341358N/A10
12/31/2025458208283N/A10
12/31/202429189119123N/A
9/30/2024242525863N/A
6/30/2024166106-23-17N/A
3/31/20249657-54-47N/A
12/31/20235111-101-89N/A
9/30/20239-30-119-104N/A
6/30/2023N/A-140-130-102N/A
3/31/2023N/A-135-152-111N/A
12/31/2022N/A-140-154-101N/A
9/30/2022N/A-130-188-99N/A
6/30/2022N/A-115-182-87N/A
3/31/2022N/A-104-137-54N/A
12/31/2021N/A-70-116-48N/A
9/30/2021N/A-58-70-35N/A
6/30/2021N/A-52-52-35N/A
3/31/2021N/A-43-45-30N/A
12/31/2020N/A-32-41-26N/A
9/30/2020N/A-27-35-25N/A
6/30/2020N/A-22-29-23N/A
3/31/2020N/A-20-28-22N/A
12/31/2019N/A-19-25-19N/A
9/30/2019N/A-17-21-15N/A
6/30/2019N/A-16-18-13N/A
3/31/2019N/A-13-14-10N/A
12/31/2018N/A-11-12-9N/A
9/30/2018N/A-9N/A-8N/A
6/30/2018N/A-11N/A-7N/A
3/31/2018N/A-10N/A-6N/A
12/31/2017N/A-8N/A-4N/A
9/30/2017N/A-7N/A-3N/A
6/30/2017N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRYS's forecast earnings growth (31.9% per year) is above the savings rate (2.8%).

Earnings vs Market: KRYS's earnings (31.9% per year) are forecast to grow faster than the US market (13.6% per year).

High Growth Earnings: KRYS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: KRYS's revenue (25.8% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: KRYS's revenue (25.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KRYS's Return on Equity is forecast to be low in 3 years time (16.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/13 02:59
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krystal Biotech, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Alec StranahanBofA Global Research
Justin ZelinB. Riley Securities, Inc.